If solid food intake is limited by nausea or early satiety, protein shakes, Greek yogurt, and collagen supplements can help meet minimum requirements without overwhelming a reduced appetite
In the SUSTAIN 6 trial, over 3,297 patients with type 2 diabetes with established chronic kidney disease and/or cardiovascular disease underwent randomization to semaglutide or placebo and were followed for 2 years resulting in a 26% risk reduction in the combined endpoint of rate of cardiovascular disease, nonfatal myocardial infarction, or nonfatal stroke [47]
Rotating sites can help prevent skin irritations
Advanced BioNutritionals GLP-1 Plus represents this modern approach by supporting not just appetite control, but overall metabolic health and quality of life improvements
Rybelsus is an FDA-approved swallowed semaglutide tablet manufactured by Novo Nordisk and absorbed through the GI tract
Amgen is developing a GLP-1/GIP dual agonist called MariTide (currently in phase 3 trials expected to complete in 2027), which is administered as a once-monthly injection